State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...
More than 9million prescriptions for Ozempic and similar weight loss drugs are written every year in the US, estimates suggest - which is one of the world's fattest nations.
The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...
Memphis-Shelby County Schools is suing multiple drug companies. Attorneys call it a mass action lawsuit, with nearly 100 other school districts across the country fighting ...
Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback